Nephrology

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.

Andrew Adams discusses tegoprubart in kidney transplantation and the phase 2 BESTOW data on kidney function, rejection, and immunosuppression.

Ramy Hanna, MD, discusses early IgAN recognition, biopsy decisions, and how emerging therapies are reshaping disease management.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

Richard Lafayette, MD, discusses how atacicept's FDA approval advances BAFF/APRIL targeting in IgA nephropathy.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

The FDA granted traditional approval to Novartis’ iptacopan (Fabhalta) for adults with primary IgA nephropathy, supported by phase 3 APPLAUSE-IgAN data showing slowed kidney function decline and sustained proteinuria reductions.

FDA grants priority review to obinutuzumab, positioning it as the first potential approved therapy for primary membranous nephropathy.

This week’s headlines include the FDA acceptance of mitapivat and roflumilast applications, the approval of atacicept for IgA nephropathy, and more.

MOTheR trial data suggest expanded hemodialysis offers comparable outcomes to online hemodiafiltration for dialysis patients, Patricia de Sequera, MD, PhD explains.

Sibeprenlimab preserved kidney function over 12 months in adults with IgA nephropathy in interim phase 3 VISIONARY trial findings.

Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.

The FDA granted accelerated approval to atacicept to reduce proteinuria in adults with primary IgAN at risk for disease progression

Here are 7 of the biggest nephrology stories from Q2 of 2026!

Andrew Bzowyckyj, PharmD, explains the transition to the 2021 CKD-EPI equation and its implications for medication decisions.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

Catch up on the nephrology headlines you missed in June 2026.

FDA sends fresh CRL for Unicycive’s OLC; manufacturing inspection delays approval, while data support a lower pill-burden phosphate binder.

Preview the biggest anticipated FDA decisions of Q3 2026, including atacicept for IgAN, mRNA flu vaccine, Furoscix ReadyFlow, and more.

Katherine Tuttle, MD, discusses shifting the goals of chronic kidney disease management from slowing progression to preserving kidney function.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.